![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
BioCryst Pharmaceuticals |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00073944 |
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
Condition | Intervention | Phase |
---|---|---|
Cancer |
Drug: forodesine hydrochloride |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies |
Study Start Date: | April 2003 |
Primary Completion Date: | January 2005 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study.
NOTE: *+/- 1 day
Patients with stable disease or better and no dose-limiting toxicity (DLT) may receive an additional 10-dose treatment course (as in course 3) after a 10- to 16-day drug-free interval.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of BCX-1777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT.
Patients are followed at 14 and 30 days.
PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following:
Non-hematologic tumor that is refractory to at least 2 prior therapies, with or without measurable disease, including the following:
Gastrointestinal adenocarcinoma of 1 of the following sites:
Not immediately eligible for any other treatment that would be potentially curative or life-prolonging, in the opinion of the investigator
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Recovered from prior therapy
United States, Ohio | |
Cleveland Clinic Taussig Cancer Center | |
Cleveland, Ohio, United States, 44195 |
Study Chair: | Alex Shalaurov, MD, PhD | Inveresk Research Group, Incorporated |
Study ID Numbers: | CDR0000341332, BIOCRYST-1777BC-101, CCF-5909 |
Study First Received: | December 10, 2003 |
Last Updated: | November 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00073944 |
Health Authority: | United States: Federal Government |
acute undifferentiated leukemia anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma atypical chronic myeloid leukemia chronic eosinophilic leukemia chronic idiopathic myelofibrosis chronic myelomonocytic leukemia chronic neutrophilic leukemia essential thrombocythemia intraocular lymphoma myelodysplastic/myeloproliferative disease, unclassifiable polycythemia vera previously treated myelodysplastic syndromes primary central nervous system lymphoma prolymphocytic leukemia |
recurrent adult acute lymphoblastic leukemia recurrent adult acute myeloid leukemia recurrent adult T-cell leukemia/lymphoma recurrent adult diffuse large cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult Burkitt lymphoma recurrent adult Hodgkin lymphoma recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma recurrent mantle cell lymphoma recurrent mycosis fungoides/Sezary syndrome |
Sezary syndrome Chronic myelogenous leukemia Hodgkin lymphoma, adult Lymphoma, small cleaved-cell, diffuse Lymphoma, large-cell, immunoblastic Preleukemia Leukemia, Prolymphocytic Hemorrhagic thrombocythemia Lymphoma, Large-Cell, Anaplastic Neoplasm Metastasis Thrombocythemia, Hemorrhagic Rectal cancer Myelodysplastic syndromes Essential thrombocytosis Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Astrocytoma Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Leukemia, Myelomonocytic, Chronic Acute myelogenous leukemia Leukemia, Myeloid Brain Neoplasms Waldenstrom Macroglobulinemia B-cell lymphomas Anaplastic large cell lymphoma Esophageal Diseases Lymphoma, Non-Hodgkin Hairy cell leukemia Lymphoma, Follicular Sezary Syndrome Lymphoma, B-Cell |